Evidence map›Paper›PMID 41331063›Full record

ArticleCommunications biology2025

Multi-omics elucidation of KDM5C, KDM6A, and KMT2B roles in cancer epigenetic dysregulation and transcriptional reprogramming.

Tengjiao Li, Lichen Wang, Shoufeng Duan, Xinyu Cui, Chunqing Fu, Jinglei Hu, Lin Li

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tengjiao Li *Shanghai Frontiers Science Center of Drug Target Identification and Delivery, Shanghai Key Laboratory for Antibody-Drug Conjugates with Innovative Target, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Lichen Wang *Shanghai Frontiers Science Center of Drug Target Identification and Delivery, Shanghai Key Laboratory for Antibody-Drug Conjugates with Innovative Target, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Shoufeng DuanShanghai Frontiers Science Center of Drug Target Identification and Delivery, Shanghai Key Laboratory for Antibody-Drug Conjugates with Innovative Target, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Xinyu CuiShanghai Frontiers Science Center of Drug Target Identification and Delivery, Shanghai Key Laboratory for Antibody-Drug Conjugates with Innovative Target, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Chunqing FuShanghai Frontiers Science Center of Drug Target Identification and Delivery, Shanghai Key Laboratory for Antibody-Drug Conjugates with Innovative Target, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Jinglei HuShanghai Frontiers Science Center of Drug Target Identification and Delivery, Shanghai Key Laboratory for Antibody-Drug Conjugates with Innovative Target, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Lin LiShanghai Frontiers Science Center of Drug Target Identification and Delivery, Shanghai Key Laboratory for Antibody-Drug Conjugates with Innovative Target, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China. linli.sjtu@sjtu.edu.cn.ORCID http://orcid.org/0000-0002-5891-9816

Funding

National Natural Science Foundation of China (National Science Foundation of China) Grant No. 22104084
6 · The paper itself

Abstract

Histone-modifying enzymes (HMEs) are critical regulators of tumorigenesis through epigenetic reprogramming. While mutations in HMEs are recognized drivers of cancer epigenome dysregulation, systematic comparative analyses of their mutational impacts and functional divergence across malignancies remain underexplored. Here, we investigated three HMEs frequently mutated in diverse cancers: KMT2B (H3K4me3 methyltransferase), KDM5C (H3K4me3 demethylase), and KDM6A (H3K27me3 demethylase). Using CRISPR/Cas9-engineered HEK293T knockout cell lines, we performed integrated multi-omics profiling that combined genome-wide chromatin accessibility, transcriptomics, and chromatin-bound proteomics. Contrary to expectations that KMT2B loss (H3K4me3 depletion) and KDM5C loss (H3K4me3 accumulation) would induce opposing transcriptional programs, or that KDM6A deficiency (H3K27me3 accumulation) would exhibit distinct regulatory effects, our analyses revealed distinct effect of all three HME modulations in terms of both transcriptional output and chromatin-associated proteomic state. Functionally, KDM5C loss upregulated FOXF2 and downregulated KLF5, implicating the dysregulation of G protein-coupled receptor pathways; KDM6A loss upregulated JUNB and downregulated TP73, affecting extracellular matrix regulation; and KMT2B loss upregulated JUN and downregulated HOXA10, impacting on cytokine signaling. Notably, transcription factors such as PATZ1 and GATA2 were commonly altered across knockouts. In PANC-1 pancreatic cancer cells, we further confirmed that KDM6A regulates CDH family genes controlling cell adhesion, thereby promoting migration and invasion. Finally, integrative analyzes demonstrated strong correlations between promoter accessibility, transcription factor occupancy, and gene expression, and uncovered cooperation between epigenetic and genetic drivers. Together, these findings reveal context-dependent functional hierarchies among HMEs and underscore the necessity of multi-layered analyses to resolve the complexity of epigenetic regulation in cancer.

Indexed as

Epigenesis, GeneticGene Expression Regulation, NeoplasticHistone DemethylasesHistone-Lysine N-MethyltransferaseNeoplasmsCell Line, TumorHEK293 CellsHumansMultiomicsProteomicsHistone DemethylasesHistone-Lysine N-MethyltransferaseKDM5C protein, humanKDM6A protein, human

Identifiers

PMID41331063
PMCPMC12783180

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.